Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5211421 | 0.91 | TNKS (0.42) | ALDH1A1MAPTTNKS | |
| SCHEMBL5215192 | 0.88 | PIN1 (0.43) | MAPTTNKS | |
| SCHEMBL5208205 | 0.86 | TP53 (0.42) | ALDH1A1TP53MAPTSMN1; SMN2TNKS | |
| SCHEMBL5208822 | 0.86 | MCHR1 (0.55) | MCHR1ATMALDH1A1CHRM1HTR2A | |
| SCHEMBL5207954 | 0.85 | RAB9A (0.42) | ALDH1A1TP53MAPTNPC1TNKS | |
| SCHEMBL5210803 | 0.84 | AURKA (0.43) | ALDH1A1TP53MAPTSMN1; SMN2HPGD | |
| SCHEMBL5212587 | 0.84 | THRB (0.50) | ALDH1A1TP53MAPTSMN1; SMN2HPGD | |
| SCHEMBL5210100 | 0.84 | PTGDR2 (0.40) | MCHR1ALDH1A1CHRM1HTR2AMAPT | |
| SCHEMBL5211745 | 0.84 | MAPT (0.41) | ALDH1A1TP53MAPTSMN1; SMN2NPC1 | |
| SCHEMBL5211475 | 0.84 | MAPT (0.41) | ALDH1A1MAPTSMN1; SMN2HPGDTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | NR1H4 150/4885MCHR1 1777/4885ATM 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.